Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats

We assessed the incidence of hemorrhagic transformation and infarct volume after early intravenous infusion of recombinant human tissue plasminogen activator (rht-PA) in a newly developed rat cerebral embolic model. Male Wistar rats (n=60) were subjected to middle cerebral artery (MCA) occlusion by a single fibrin rich clot. One hour after embolization, rats were assigned to the following groups: (1) rht-PA treated group (n=20); (2) vehicle treated group (n=20); and (3) saline treated group (n=20). Neurological deficits, lodgement of a clot at the origin of the MCA, infarction volume and microscopic hemorrhage were measured. Animals exhibited moderate to severe neurological deficits 1 h after MCA occlusion in all groups. Administration of rht-PA significantly (P<0.05) reduced the incidence of lodgement of a clot at the origin of the MCA (30%) compared with the saline treated group (100%) and the vehicle treated group (80%). A significant (P<0.05) reduction of percent hemispheric infarct volume was detected between the saline (33.2+/-3.71%) and the rht-PA groups (19.4+/-3.3%). However, no significant difference was found in the total area of microscopic hemorrhage of the rht-PA (0.05+/-0.02 mm2), the vehicle (0.02+/-0.01 mm2), and the saline (0.03+/-0.02 mm2) treated groups. No significant difference of percent hemispheric infarct volume (P=0.08) was observed between the vehicle and the rht-PA treated groups. This study demonstrates that treatment with rht-PA reduced infarct volume without increasing intracerebral hemorrhage in rats with large cerebral infarction when treatment was initiated at 1 h of the onset of embolization.

[1]  J. Zabramski,et al.  A Comparison of Intra‐arterial and Intravenous Tissue‐Type Plasminogen Activator on Autologous Arterial Emboli in the Cerebral Circulation of Rabbits , 1994, Stroke.

[2]  W. Hacke,et al.  'Malignant' middle cerebral artery territory infarction : Clinical course and prognostic signs , 1996 .

[3]  B. Keyt,et al.  A Long‐Half‐life and Fibrin‐Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding , 1994, Stroke.

[4]  J. Ogata,et al.  Hemorrhagic infarct induced by arterial hypertension in cat brain following middle cerebral artery occlusion. , 1990, Stroke.

[5]  G. Hamann,et al.  Hemorrhagic Transformation and Microvascular Integrity during Focal Cerebral Ischemia/Reperfusion , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  G. Boysen,et al.  Effect of Delayed Thrombolysis with rt-PA in a Rat Embolic Stroke Model , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  J. Rothrock,et al.  Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. , 1987, Archives of neurology.

[8]  W. Hacke,et al.  Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. , 1990, Stroke.

[9]  J. Broderick,et al.  Factors Related to Intracranial Hematoma Formation in Patients Receiving Tissue‐Type Plasminogen Activator forAcute Ischemic Stroke , 1994, Stroke.

[10]  M. Chopp,et al.  Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient (2h) but not after permanent MCA occlusion in the rat , 1994 .

[11]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[12]  G. Boysen,et al.  Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model. , 1993, Scandinavian journal of clinical and laboratory investigation.

[13]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[14]  A. Torvik,et al.  Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. , 1969, Journal of the neurological sciences.

[15]  G. Boysen,et al.  A Rat Model of Reproducible Cerebral Infarction Using Thrombotic Blood Clot Emboli , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  M. Moskowitz,et al.  L-Arginine Infusion Promotes Nitric Oxide-Dependent Vasodilation, Increases Regional Cerebral Blood Flow, and Reduces Infarction Volume in the Rat , 1994, Stroke.

[17]  K Ohta,et al.  Repeat Positron Emission Tomographic Studies in Transient Middle Cerebral Artery Occlusion in Cats: Residual Perfusion and Efficacy of Postischemic Reperfusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  T. Pryor,et al.  Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. , 1991, The American journal of cardiology.

[19]  A. Torvik,et al.  Ischaemic cerebrovascular diseases in an autopsy series , 1966 .

[20]  C. Weiller,et al.  Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization , 1992, Neurology.

[21]  M. Fisher,et al.  The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model , 1988, Annals of neurology.

[22]  R A Swanson,et al.  A Semiautomated Method for Measuring Brain Infarct Volume , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  W. Pulsinelli,et al.  Hemorrhagic complications of thrombolytic therapy in experimental stroke. , 1987, Stroke.

[24]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[25]  P. Lyden,et al.  Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke , 1988 .

[26]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.

[27]  P. Penar,et al.  The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. , 1987, The Yale journal of biology and medicine.

[28]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[29]  E. Topol,et al.  Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. , 1987, Journal of neurosurgery.

[30]  Michael Chopp,et al.  A rat model of focal embolic cerebral ischemia , 1997, Brain Research.

[31]  Lyden Pd,et al.  Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. , 1993, Cerebrovascular and brain metabolism reviews.

[32]  U. Degirolami,et al.  Tissue plasminogen activator reduces neurological damage after cerebral embolism. , 1985, Science.